The strategy of developing personalized protocols of aesthetic intervention for patients with medical weight loss (MWL) is a relevant task for cosmetologists in the current realities, since the number of such patients is rapidly increasing, which causes high demand. This article presents an algorithm for comprehensive aesthetic support for a patient in the process of losing weight. 

Background. Dermatocosmetics containing active ingredients that reduce the severity of the disease symptoms play an important role in the skin care of patients suffering from acne. They are used independently and in combination with drug therapy, improving its tolerability and results. Basic care includes cleansing, moisturizing, and sunscreen products.
Methods. An international group of experts of dermatology with experience in the treatment of acne conducted a literature review and formulated questions regarding the impact of dermatocosmetics on the course of the disease, both independently and in combination with drug treatments. Based on the literature data and their own experience, the experts answered the questions and formulated recommendations for the use of dermatocosmetics in the treatment of acne.
Results. The experts confirmed that dermatocosmetics improve the course of the disease in mild cases, reduce the number of rashes, reduce skin oiliness, and are well tolerated by patients. In combination with medical treatment – improves the results of the latter, its tolerability, increases the compliance of treatment. The important role of dermatocosmetics in the prevention and elimination of post‑inflammatory hyperpigmentation is noted.
Conclusion. Despite the low quality of evidence associated with a limited number of studies, dermatocosmetics has shown effectiveness when used independently for mild acne and adjunct to drug treatment.

The article provides a general description of dermatomycetes (dermatophytes) as a non-systematic group of parasitic fungi, data on the factors of their aggression and virulence are summarized, and the main features of the clinical picture of skin mycosis caused by T. indotineae (indotine‑ mycosis), a new fungus, which many molecular geneticists consider to be an independent species, are listed. Doubts are expressed about the self-activity of this species within the genus Trichophyton, since to date there has been practically no serious microbiological description of its macro‑ and micromorphology. The clinical picture of skin mycosis caused by T. indotineae fully fits into the concept of «trichophytia», as this mycosis should be further classified.

Hypertrophic scars represent a common clinical complication arising from impaired wound healing and tissue regeneration processes, leading to significant aesthetic, functional, and psychological consequences that markedly reduce patients’ quality of life. This review evaluates the clinical significance and therapeutic efficacy of capacitive resistive electric transfer (CRET) therapy at 448 kHz for managing pathological scar formation. The findings demonstrate that CRET therapy effectively modulates inflammatory responses, regulates collagen synthesis, promotes tissue remodeling, and enhances skin elasticity. This non invasive therapeutic modality shows substantial clinical potential as a device based treatment approach that significantly improves patient outcomes by reducing fibrotic manifestations and optimizing wound healing processes.

Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and immune dysregulation. It is associated with genetic predisposition, autoimmune disorders, comorbid pathology, mental and psychological diseases, and environmental factors. The objective of this study was to study the prevalence of palmar-plantar psoriasis in a general cohort of patients with psoriasis and to identify the main risk factors for the development of this phenotype of dermatosis. For this purpose, the analysis of clinical and anamnestic data was carried out in patients with a diagnosis of psoriasis. In total, the study group included 757 patients with various phenotypes of psoriasis, whose data were analyzed in the general cohort and further based on the division of patients by the presence of LPP (2 groups), while comparing all clinical and anamnestic data in the context of the presence of lesions in the localization of the palms and soles.

Failure to promptly detect early signs of structural damage in PsA can lead to the development of serious irreversible joint damage, which in turn can cause disability and a significant reduction in quality of life. Furthermore, late detection of PsA is associated with a significant reduction in the effectiveness of therapy. Therefore, the importance of early, active treatment, including the use of biologic agents, for secondary prevention of PsA is now clear. This treatment aims to slow progression and prevent disability.
Material and methods. The study included 21 patients with glabrous psoriasis, as well as those with early signs of psoriatic arthritis, particularly with axial lesions affecting the spine and sacroiliac joints. Treatment with netakimab was administered according to the following regimen: 120 mg at weeks 0, 1, and 2, then 120 mg of netakimab monthly for 52 weeks.
Results. By week 52, 95.24% of patients achieved a PASI of 100. Magnetic resonance imaging (MRI) of the sacroiliac joints using the STIR mode revealed no signs of active inflammation by week 12 of therapy in 85.71% of patients. Cervical spine radiography also showed no structural damage. Netakimab significantly reduced axial manifestations of Ps A. All patients reported a reduction in inflammatory back pain by week 12 of treatment, as evidenced by changes in the BASDAI score.
Conclusions. The strategy of early administration of biologic agents such as netakimab to patients with severe and moderate skin psoriasis and early signs of PsA in the back appears justified. This strategy may help prevent disability, a significant reduction in quality of life, and irreversible changes in joints. Furthermore, this therapy helps reduce systemic inflammation, which may be considered an important aspect of secondary prevention of the development of severe forms of psoriatic arthritis in the future.

The article describes the main etiopathogenetic factors of acne development, including hormonal mechanisms. Modern advances in dermatology and endocrinology make it possible to develop new, more effective and safer treatment methods based on the molecular and clinical analysis of each patient. A personalized approach, integration of data on hormonal status, lipid profile and microbiota opens up prospects for individualizing therapy, increasing its effectiveness and improving the prognosis of the disease.

Розацеа – сложное мультифакториальное заболевание, в развитии которого важную роль играют генетические, иммунные и внешние факторы. Современные исследования позволяют лучше понять молекулярные механизмы патогенеза, что открывает возможности для разработки новых методов диагностики и терапии, учитывающих индивидуальные особенности каждого пациента. В настоящем исследовании был проведен комплексный анализ демографических, клинических и сопутствующих характеристик у пациентов с разными типами розацеа, что позволяет обобщить особенности их распределения и взаимосвязи. Получены данные, что наиболее старший возраст и мужской пол характерны для пациентов с фиматозным типом розацеа, тогда как остальные формы чаще встречаются у женщин среднего возраста. Папуло‑пустулезный тип ассоциирован с максимальной частотой нарушений углеводного обмена, патологии ЖКТ и дислипидемии. Эритематозно‑телангиэктатический тип характеризуется высокой распространенностью артериальной гипертензии, стрессовых факторов, курения и УФ‑экспозиции. Особенности образа жизни (стресс, курение, диета, употребление алкоголя) и сопутствующие заболевания существенно различаются в зависимости от типа розацеа, что требует индивидуализированного подхода к лечению и профилактике.

Acne relapse following completion of systemic isotretinoin therapy remains a significant clinical problem, with recurrence rates ranging from 9% to 65%. This review analyzes existing data on potential predictors of acne relapse and the role of cumulative dose and various daily dosing regimens of systemic isotretinoin in maintaining long‑term remission. We emphasize that the lack of comparability in results across different studies is largely due to methodological differences (heterogeneous patient populations, the absence of a standardized definition for «acne relapse»). The article underscores the urgent need to unify relapse criteria for a comprehensive assessment of prognostic factors to create personalized treatment approaches for acne patients, taking into account the individual relapse risks and optimizing systemic isotretinoin dosing regimens.

Introduction. Malignant neoplasms remain one of the leading causes of mortality worldwide, contributing to the increasing number of patients requiring systemic anticancer therapy. The introduction of immune checkpoint inhibitors (ICIs) has been a breakthrough in oncology, significantly improving survival in several malignancies. However, their use is associated with the development of immune‑related adverse events (irAEs), among which immune‑related dermatologic adverse events (irDAEs) are the most common.
Objective. To research the clinical features of immune-related dermatologic adverse events in patients receiving immunotherapy at Moscow State Budgetary Healthcare Institution «Oncological Center No.1 of Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department»
Materials and methods. A prospective, single‑center study included 171 patients who received therapy with PD‑1/PD‑L1 inhibitors (pembrolizumab, nivolumab, prolgolimab, atezolizumab, avelumab) during the period 2023–2025 at Oncology Center No. 1, S.S. Yudin City Clinical Hospital, Moscow. The study focused on immune-related dermatologic adverse events (irDAEs) associated with anticancer immunotherapy in oncology patients, with an emphasis on identifying their clinical characteristics. The classification of irDAEs was based on clinical presentation and dermatoscopic findings. Data collection was performed using MS Excel 2019, and statistical analysis was carried out using StatTech v.4.8.11.
Results. The study included 171 patients (57.3% male, mean age 67.2 years). The most common primary malignancies were skin and soft tissue cancers (35.1%) and genitourinary cancers (32.2%). A wide spectrum of immune‑related dermatologic adverse events was identified during therapy. The most frequently observed events were maculopapular rash (31%), isolated pruritus (20.5%), and psoriasiform eruptions (17%). Less commonly, exacerbation of pre‑existing psoriasis (12.9%), lichenoid eruptions (9.9%), vitiligo (4.1%), and bullous pemphigoid (4.1%) were recorded. The rarest manifestations included erythema nodosum (2.3%) and scleroderma‑like reactions (2.3%).
Conclusion. Immune‑related dermatologic adverse events during PD‑1/PD‑L1 inhibitor therapy range from early manifestations, such as maculopapular rash and pruritus, to rare but severe conditions, including bullous pemphigoid and scleroderma‑like reactions. Timely diagnosis and appropriate management are essential to maintain patients’ quality of life and ensure the continuity of anticancer immunotherapy.

Gorlin‑Goltz syndrome (GGS) is a rare autosomal dominant disorder caused by mutations in the PTCH1 and SUFU genes, key components of the Sonic Hedgehog signaling pathway. GGS is characterized by a high risk of developing tumors, primarily basal cell carcinoma (BCC) and medulloblastoma. The article presents a clinical case of an 11‑year‑old patient with PTCH1‑associated GGS, who was diagnosed with medulloblastoma at the age of 3 years, and by the age of 6 years, multiple basal cell skin cancer manifested. The clinical case highlights the importance of early diagnosis, timely molecular genetic testing and interdisciplinary monitoring to improve the prognosis and quality of life of patients with this syndrome.

The article presents the successful treatment of patient S. 15 years old with fulminant acne which may have developed due to an error in the simultaneous administration of doxycycline and isotretinoin. Despite a severe complication characterized by an island‑inflammatory reaction with the formation of nodules, pustules and erosive and ulcerative defects, stable remission was achieved. A key role in this was played by the strategy of consistent use of systemic glucocorticoids (prednisone), followed by gradual incorporation and titration of the dose of isotretinoin in the form of Lidose. The drug has demonstrated good tolerability and effectiveness even in a difficult clinical situation, making it possible to complete the full course of therapy with the achievement of the course dose. Lidose technology, which provides improved bioavailability regardless of food intake, is particularly valuable for patients whose lifestyle or gastrointestinal side effects make it difficult to comply with strict rules for taking standard isotretinoin. The article also discusses modern laser methods for correcting post‑acne residual phenomena.

Introduction. Management of patients with inverse psoriasis presents a significant challenge due to diagnostic complexity and pronounced psycho‑emotional distress. Current clinical guidelines recommend zinc pyrithione as one therapeutic option.
Objective. To demonstrate the clinical efficacy of activated zinc pyrithione–based medications (Skin‑Cap) in patients with inverse psoriasis.
Materials and methods. This article describes seven clinical cases involving various formulations of Skin‑Cap, used either as monotherapy or in combination with other drugs.
Results. The reported clinical observations show high efficacy and safety of Skin‑Cap in multiple topical forms (aerosol, cream, shampoo, shower gel) for treating inverse psoriasis, in both short‑term and long‑term use.
Conclusions. The use of Skin‑Cap in the topical treatment of inverse psoriasis is pathogenetically justified, minimizes the risk of adverse effects, and significantly improves patients’ quality of life.

Melasma is a common, chronic, and recurrent pigmentation disorder caused by excessive melanin deposition in the epidermal and dermal layers of the skin. The treatment strategy for melasma presents a complex challenge, as it depends on the severity of the condition and the individual characteristics of the patient. One effective method for treating melasma is the combined use of laser therapy and the topical application of tranexamic acid, which has the property of reducing melanogenesis activity.
Objective. To compare the efficacy and safety of melasma treatment using CO2-laser monotherapy versus a combination of laser therapy and the topical application of tranexamic acid.
Materials and methods. The study included 20 patients, 10 of whom underwent three combined procedures of fractional photothermolysis using a CO2‑aser (10600 nm) followed by the application of a 5% tranexamic acid solution at 4‑week intervals. The other 10 patients received only the CO2‑laser procedure at the same intervals. Quantitative assessment methods included the Melasma Area and Severity Index (MASI), mexametry, and the Melasma Quality of Life scale (MELASQOL). Clinical evaluation was also performed using the «Antera» 3D skin imaging and diagnostic device.
Conclusions. The use of a CO3‑laser followed by the application of a 5% tranexamic acid solution demonstrated greater effectiveness compared to laser therapy alone.

Acne‑induced post‑inflammatory hyperpigmentation is a common consequence of acne development, which contributes to patient dissatisfaction with the results of therapy. The pathophysiology of this type of dyschromia is a complex set of interactions between changes in the cellular structures of the skin, disruptions in the functioning of various signaling pathways and the immune response induced by the activity of bacterial biota. Retinoids are integral means of drug therapy for acne, which are also actively used for the prevention and treatment of various conditions accompanied by increased melanogenesis. Trifarotene is a 4th generation retinoid selective for RARγ. The conducted phase IV study LEAP (AkLief Evaluation in Acne‑induced Post‑inflammatory hyperpigmentation) showed that trifarotene contributes to an active decrease in the severity of skin pigmentation with the achievement of a significant clinical effect on acne manifestations. Modern scientific achievements make it possible to take the path of timely prevention and elimination of persistent cosmetic defects that develop as a result of acne.

Introduction. Skin type classification is a key tool in dermatological and cosmetological practice, providing the foundation for diagnosis and personalized care. The most widely known system is the Leslie Baumann typology, which includes 16 skin types and is commonly used in international practice. However, its application in the Russian population has revealed several limitations: the system does not account for normal and combination skin types while combination skin is predominant among respondents; and it does not incorporate acne proneness, one of the most common dermatological conditions.
Purpose of the study. 1. To assess the diagnostic accuracy and adaptability of the Doc.Skin methodology compared with the Baumann typology in the Russian population. 2. To conduct a clinical validation of the Doc.Skin system by comparing its results with dermatologists’ assessments.
Materials and methods. A single‑center prospective comparative diagnostic study was conducted in two stages. In the first stage, 1,687 respondents completed an online diagnosis using the Doc.Skin system, which is based on artificial intelligence (AI). In the second stage, 250 participants underwent online diagnosis with Doc.Skin immediately prior to in‑person examination. Skin type and its characteristics were verified by board‑certified dermatologists, who were blinded to the system’s outputs. Expert assessments were then compared with the results of Doc.Skin to evaluate its diagnostic accuracy.
Results. Combination skin was the predominant type in the Russian population (43%), followed by normal (24%), dry (18%), and oily (16%). Thus, the Baumann typology, which includes only two basic skin types: dry and oily – covered just 34% of the sample, substantially limiting its diagnostic value in this population. Acne proneness, not represented in the Baumann typology, was identified to varying degrees in 51% of participants and ranked second among prevalent skin concerns. Consequently, the overall adaptability of the Baumann methodology, considering all basic types and skin concerns, was only 17.2 %, compared with the diagnostic coverage of the Doc.Skin system. In the second stage, a high level of concordance was observed between AI‑based Doc.Skin results and dermatologists’ clinical assessments: concordance in skin type and characteristic definitions reached 98.3%.
Conclusions. The AI‑based Doc.Skin diagnostic system, which incorporates 64 skin types and accounts for key characteristics such as sensitivity, acne, wrinkles, and pigmentation, demonstrated high diagnostic accuracy and clinical validity. The methodology can be considered a reliable tool for skin classification in the Russian population and may be applied by dermatologists, healthcare professionals, and in consumer applications to provide personalized skin care recommendations.

This study aimed to determine the basic physicochemical properties (viscosity, pH, particle size, distribution, and stability) of a formulation based on polylactic acid (PDLLA – 42.5 mg) and sodium hyaluronate (HA ‑ 7.5 mg) and a formulation based on polylactic acid (PDLLA – 170 mg) and sodium hyaluronate (HA – 30 mg). The following objectives were addressed: determining the viscosity and pH of the formulation solutions at control points of 30 minutes, 12 hours, and 24 hours; determining the particle size, distribution, and stability; and the presence of BDDE. The viscosity results of the formulation solutions at control points of 12 and 24 hours were similar for both formulations. At the 30‑minute post‑dilution checkpoint, the viscosity differed. This may be due to the biodegradation of hyaluronic acid in PDLLA‑170 mg, as its content differs in the two solutions. The pH of the PDLLA‑42.5 mg solutions at the 30‑minute, 12‑hour, and 24‑hour checkpoints showed a slight decrease, while that of the PDLLA‑170 mg solution remained virtually unchanged throughout the experiment. Furthermore, the changes in pH for both solutions can be considered insignificant. The particle size of the PDLLA‑42.5 mg solutions after dehydration ranged from 20 µm to 40 µm, while that of the PDLLA‑170 mg solutions ranged from 40 µm to 80 µm. Particle distribution and stability parameters for PDLLA‑42.5 mg solutions showed minor changes over time, while for particles from PDLLA‑170 mg solutions, these parameters remained virtually unchanged over the course of the experiment. For both solutions, these parameters remained within normal limits. The presence of BDDE in both PDLLA solutions was not confirmed.

In recent decades, the issues of rehabilitation of patients after plastic surgery, in particular after endoscopic lifting, have become particularly important due to the increasing demand for anti‑aging procedures. The objective of our study was to carry out a comparative analysis of changes in microcirculation and the rate of tissue repair, including reduction of swelling and normalization of trophism, in the postoperative period after endoscopic eyebrow lifting using standard rehabilitation, microcurrent therapy, neodymium laser and their combination using ultrasound, capillaroscopy and thermography data. The results have been obtained that the use of physiotherapeutic methods in the early rehabilitation period contributes more to the relief of edema, inflammation, and improvement of hemodynamic parameters at an earlier date, while the combined use of a neodymium laser and microcurrent therapy has an advantage over mono effects of these physical factors.

Telogen effluvium (TE) is one of the most common diseases accompanied by hair loss. The main pathogenetic mechanism of TE is the premature transition of hair follicles from the anagen phase to the telogen phase. In the absence of a single standard treatment, physiotherapeutic methods aimed at activating hair growth by stimulating cell activity and energy metabolism are of particular interest. One of the most promising methods is low-intensity laser therapy, which promotes increased ATP synthesis and activation of signalling pathways that regulate the growth and differentiation of hair follicle cells. High‑intensity ablative and non‑ablative lasers not only stimulate hair growth but also improve transdermal drug delivery. In addition, methods using radiofrequency and electrical stimulation enhance cell proliferation, growth factor expression and tissue regeneration processes. Scientific studies confirm the effectiveness of these methods and demonstrate their potential for use in both monotherapy and combined protocols. Thus, physiotherapeutic technologies open up opportunities for the creation of pathogenetically sound methods for the treatment of telogen alopecia.

Melasma is a chronic acquired skin condition (melanodermia) characterized by the formation of pigmented spots on the face, predominantly in the forehead, cheeks, and upper lip areas. This condition can have a significant negative impact on the psychosocial well‑being and quality of life of patients. Therefore, effective treatment methods and an evaluation of their impact on quality of life are necessary.
Objective of the study. To compare the effectiveness and safety of combined CO2‑laser therapy and topical tranexamic acid solution with CO2-laser monotherapy in improving the quality of life of patients with melasma, assessed using the MELASQoL scale.
Materials and methods. The study included 40 patients with clinical manifestations of melasma on the face. Half of the participants (main group) underwent 3 combined fractional photothermolysis procedures using a CO2‑laser (10600 nm), followed by the application of a 5% tranexamic acid solution with a 4‑week interval. The other half (control group) received monotherapy with only the CO2‑laser at the same intervals. Two indices were used to assess therapeutic dynamics: the Melasma Area and Severity Index (MASI) and the Melasma Quality of Life scale (MELASQoL).
Conclusions. Combined therapy with fractional CO2‑laser and tranexamic acid is superior to laser monotherapy in improving the quality of life of patients with melasma, as confirmed by a significant reduction in MELASQoL scores. The assessment of quality of life using MELASQoL is an important tool for the comprehensive evaluation of melasma treatment effectiveness.

Hyaluronic acid (HA) is a key biopolymer in injection cosmetology, regulating processes of tissue regeneration, inflammation, and hydration. Its functional polymorphism, determined by variability in molecular weight (MW), spatial organization, and receptor interactions, defines the duality of its biological effects. This dichotomy positions HA as a central focus of research in biomedicine and cosmetology, where controlling its properties opens pathways to personalized therapeutic strategies. Modern injection cosmetology faces challenges related to limitations in the use of native hyaluronic acid and traditional cross‑linked HA fillers. Rapid biodegradation of native HA by reactive oxygen and nitrogen species, as well as hyaluronidases, further diminishes long‑term efficacy. Despite their ability to correct volume deficits, dermal fillers do not address the pathogenetic mechanisms of aging, and their application carries risks of adverse reactions due to residual cross‑linker content. These problems highlight the need for innovative approaches to polymer stabilization, MW control, and the integration of bioactive components to synergize volumetric correction with biochemical impact. Solid‑phase modification methods for HA hold promise – specifically, mechanochemical cross‑linking with bio‑regulators, which eliminates toxic reagents and ensures controlled delivery of active agents. The relevance of this work stems from the necessity to transition from symptomatic correction to pathogenetically‑grounded interventions in injection cosmetology. Despite the broad spectrum of existing preparations, the selection of optimal HA forms is often based on empirical data, leading to variable outcomes and complication risks. Systematizing current scientific evidence on the influence of HA molecular weight, post‑synthetic modifications, and receptor interactions on procedural efficacy is a crucial step towards establishing pathogenetically‑grounded protocols that minimize the risk of complications.

Background. Rosacea is a chronic inflammatory skin condition with a multifactorial aetiology and a wide range of clinical manifestations. Erythematotelangiectatic rosacea (ETR) is difficult to treat and maintain in remission due to the limited range of effective methods for erythema management.
Aim. To increase the effectiveness of the ETR treatment by developing a scientifically based algorithm for comprehensive restorative treatment involving physical therapy and botulinum toxin.
Materials and methods. A single‑centre open‑label prospective randomized study was conducted between 2022 and 2025. A total of 117 patients with ETR were enrolled in the study and divided into four groups. Four treatment options for ETR were analyzed: monotherapy with a pulsed dye laser (PDL, comparison group), and three options for complex therapy, including physiotherapy (pulsed dye laser, local dynamic micromassage) and botulinum toxin therapy. Follow‑up examinations were conducted over a period of 6 months at five points: before the start of treatment, 2 weeks, 2 months, 4 months and 6 months after the end of therapy. Therapy effectiveness was assessed using a dermatological index of the symptom scale, a clinical erythema assessment scale (CEA), a subjective erythema assessment scale (SSR).
Results. According to the dynamics of the dermatological index of the symptom scale, only in the group of patients receiving complex treatment with PDL, LDM and botulinum toxin type A was almost complete resolution of clinical manifestations of ETR achieved after 2 months, with minimal symptoms of dermatosis by the 4th month of dynamic observation. An intergroup comparison confirmed that the lowest dermatological index of the symptom scale scores at all control points of the study were observed in group 4, which received complex treatment with PDL, LDM and botulinum toxin type A (p<0.001). When assessing the effectiveness of the developed methods of treating ETR in relation to erythema according to the CEA and SSR scales, already at the second control point, against the background of complex treatment with PDL, LDM and botulinum toxin type A, there was complete/almost complete resolution of erythema according to both the investigator and the patients. The achieved result persisted up to 6 months of observation according to the CEA scale, while patients noted a slight progression of the skin pathological process already 4 months after the end of therapy.
Conclusion. The results presented herein demonstrated the high clinical efficacy of a complex treatment regimen for ETR, including application of a pulsed dye laser, local dynamic micromassage, and botulinum toxin type A.

Seborrheic dermatitis is a chronic recurrent inflammatory dermatosis that manifests as erythematous macules or plaques in sebaceous areas. The main components of pathogenesis seborrheic dermatitis: activation of sebaceous glands secretion, Malassezia fungi colonization of the skin, specific immune response. Manifest and recurrences of seborrheic dermatitis depend on individual triggers: impairment of epidermal barrier, genetic factors, neurogenic factors, emotional stress, nutrition, metabolic disorders.
Objective. To identify risk for the development and recurrences of seborrheic dermatitis, to describe the comorbidities, to review the modern methods of treatment of seborrheic dermatitis.
Materials and methods. Article searches were performed in PubMed, Google Scholar, Elibrary over the period from 10 years to 01.02.2025 for the keywords ‘seborrheic dermatitis’, ‘risk factors’, ‘differential diagnosis’, ‘treatment of seborrheic dermatitis’.
Results. The review included 65 publications. Risk factors for the development of seborrheic dermatitis include exogenous (environmental conditions, medications, nutrition) and endogenous factors (male gender, genetics, immune response, comorbidities, psychoemotional stress, metabolic syndrome).
Conclusions. Trigger factors of the development of dermatosis can help to select more effective therapy of seborrheic dermatitis. Research the pathogenesis of seborrheic dermatitis and associated diseases may open new therapeutic targets for the treatment of seborrheic dermatitis.